OS Win for Enzalutamide in Prostate Cancer at High Risk for Biochemical Recurrence

(MedPage Today) — BERLIN — Combining enzalutamide (Xtandi) with androgen deprivation therapy (ADT) significantly improved overall survival (OS) in prostate cancer patients at high risk of biochemical recurrence, according to results from…